Dataset Information

Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women.

ABSTRACT:

Objective

To test whether alternate-day low-dose aspirin affects incidence of age-related macular degeneration (AMD) in a large-scale randomized trial of women.

Design

Randomized, double-masked, placebo-controlled trial.

Participants

Thirty-nine thousand eight hundred seventy-six healthy female health professionals aged 45 years or older.

Intervention

Participants were assigned randomly to receive either 100 mg aspirin on alternate days or placebo and were followed up for the presence of AMD for an average of 10 years.

Main outcome measures

Incident AMD responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-report confirmed by medical record review.

Results

After 10 years of treatment and follow-up, there were 111 cases of AMD in the aspirin group and 134 cases in the placebo group (hazard ratio, 0.82; 95% confidence interval, 0.64-1.06).

Conclusions

In a large-scale randomized trial of female health professionals with 10 years of treatment and follow-up, low-dose aspirin had no large beneficial or harmful effect on risk of AMD.

SUBMITTER: Christen WG

PROVIDER: S-EPMC2787838 | biostudies-literature | 2009 Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women.

Christen William G WG Glynn Robert J RJ Chew Emily Y EY Buring Julie E JE

Ophthalmology 20091007 12

<h4>Objective</h4>To test whether alternate-day low-dose aspirin affects incidence of age-related macular degeneration (AMD) in a large-scale randomized trial of women.<h4>Design</h4>Randomized, double-masked, placebo-controlled trial.<h4>Participants</h4>Thirty-nine thousand eight hundred seventy-six healthy female health professionals aged 45 years or older.<h4>Intervention</h4>Participants were assigned randomly to receive either 100 mg aspirin on alternate days or placebo and were followed u ...[more]

PMID: 19815293

Similar Datasets

Project description:ObjectiveTo examine the survival outcomes in women with endometrial cancer who were taking low-dose aspirin (81-100 mg/d).MethodsA multicenter retrospective study was conducted examining patients with stage I-IV endometrial cancer who underwent hysterectomy-based surgical staging between January 2000 and December 2013 (N=1,687). Patient demographics, medical comorbidities, medication types, tumor characteristics, and treatment patterns were correlated to survival outcomes. A Cox proportional hazard regression model was used to estimate adjusted hazard ratio for disease-free and disease-specific overall survival.ResultsOne hundred fifty-eight patients (9.4%, 95% confidence interval [CI] 8.8-11.9) were taking low-dose aspirin. Median follow-up time for the study cohort was 31.5 months. One hundred twenty-seven patients (7.5%) died of endometrial cancer. Low-dose aspirin use was significantly correlated with concurrent obesity, hypertension, diabetes mellitus, and hypercholesterolemia (all P<.001). Low-dose aspirin users were more likely to take other antihypertensive, antiglycemic, and anticholesterol agents (all P<.05). Low-dose aspirin use was not associated with histologic subtype, tumor grade, nodal metastasis, or cancer stage (all P>.05). On multivariable analysis, low-dose aspirin use remained an independent prognostic factor associated with an improved 5-year disease-free survival rate (90.6% compared with 80.9%, adjusted hazard ratio 0.46, 95% CI 0.25-0.86, P=.014) and disease-specific overall survival rate (96.4% compared with 87.3%, adjusted hazard ratio 0.23, 95% CI 0.08-0.64, P=.005). The increased survival effect noted with low-dose aspirin use was greatest in patients whose age was younger than 60 years (5-year disease-free survival rates, 93.9% compared with 84.0%, P=.013), body mass index was 30 or greater (92.2% compared with 81.4%, P=.027), who had type I cancer (96.5% compared with 88.6%, P=.029), and who received postoperative whole pelvic radiotherapy (88.2% compared with 61.5%, P=.014). These four factors remained significant for disease-specific overall survival (all P<.05).ConclusionOur results suggest that low-dose aspirin use is associated with improved survival outcomes in women with endometrial cancer, especially in those who are young, obese, with low-grade disease, and who receive postoperative radiotherapy.

Dataset Information

Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women.

Objective

Design

Participants

Intervention

Main outcome measures

Results

Conclusions

Publications

Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets